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We performed genome-wide homozygosity mapping and mapped a novel myopathic phenotype to chromosomal region 1q25 in a
consanguineous family with three affected individuals manifesting proximal and distal weakness and atrophy, rigid spine and
contractures of the proximal and distal interphalangeal hand joints. Additionally, cardiomyopathy and respiratory involvement were
noted. DNA sequencing of torsinA-interacting protein 1 (TOR1AIP1) gene encoding lamina-associated polypeptide 1B (LAP1B),
showed a homozygous c.186delG mutation that causes a frameshift resulting in a premature stop codon (p.E62fsTer25). We observed
that expression of LAP1B was absent in the patient skeletal muscle fibres. Ultrastructural examination showed intact sarcomeric
organization but alterations of the nuclear envelope including nuclear fragmentation, chromatin bleb formation and naked
chromatin. LAP1B is a type-2 integral membrane protein localized in the inner nuclear membrane that binds to both A- and B-type
lamins, and is involved in the regulation of torsinA ATPase. Interestingly, luminal domain-like LAP1 (LULL1)—an endoplasmic
reticulum-localized partner of torsinA—was overexpressed in the patient’s muscle in the absence of LAP1B. Therefore, the findings
suggest that LAP1 and LULL1 might have a compensatory effect on each other. This study expands the spectrum of genes
associated with nuclear envelopathies and highlights the critical function for LAP1B in striated muscle.
 2014 Elsevier B.V. All rights reserved.
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Muscular dystrophies are a clinically and genetically
heterogeneous group of hereditary muscle disorders
characterized by progressive muscular degeneration and
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is limb-girdle muscular dystrophies, which predominantly
present with proximal weakness with sparing of the facial
and distal muscles, and cardiomyopathy in some subtypes
[2]; however even when the disease begins with
limb-girdle weakness, additional clinical features lead to
consider other myopathic disorders. When limb-girdle
weakness is combined with early distal muscle
involvement, contractures and cardiac involvement, the
phenotype is usually categorized as Emery–Dreifuss
muscular dystrophy (EDMD) [3,4]. On the other hand,
additional characteristic features of the phenotype such
as early and non-proportional weakness, and atrophy of
the distal muscles, are indicative of myopathies with
predominantly distal muscle involvement [5,6]. To date,
some patients are affected with muscular dystrophy of
unknown genetic aetiology, and some families are not
linked to any of the known loci.
Lamina-associated polypeptide 1s (LAP1s) were
originally identified as three integral membrane proteins
(LAP1A, LAP1B and LAP1C) specific to the nuclear
envelope in the rat liver [7]. To date, TOR1AIP1
(torsinA-interacting protein 1 gene) encoding LAP1B
protein is the only cloned human lamina-associated
polypeptide 1 [8]. Despite the fact that the function of
LAP1B is currently not fully known, this type-2 integral
membrane protein located in the inner nuclear membrane
is known to bind both A- and B-type lamins [7–10].
Subsequently, LAP1 has been implicated in the regulation
of torsinA ATPase which is known to cause the severe
movement disorder DYT1 dystonia (MIM 128100)
[11,12]. Another torsinA-interacting protein, luminal
domain-like LAP1 (LULL1) encoded by TOR1AIP2 is
located in the endoplasmic reticulum and shares
homologous C-terminal regions with LAP1 allowing
interaction with torsinA. These two proteins appear to
have arisen from a gene duplication [11]. LAP1B is
widely expressed in a variety of tissues, including skeletal
muscle [11,13]. To date LAP1B has not been reported to
be involved in any disease.
Mutations in several genes that encode proteins of the
nuclear envelope such as lamin A/C, lamin B, lamin B
receptor, nesprin-1, nesprin-2 and emerin are known to
cause defects of the nuclear envelope. This group of
diseases known as nuclear envelopathies consist of a wide
range of clinical syndromes, including muscular dystrophy,
cardiomyopathy, lipodystrophy, mandibuloacral
dysplasia, neuropathy, progeria, restrictive dermopathy,
arthrogryposis, Pelger–Huet anomaly and leukodystrophy
[14,15].
Herein we report a consanguineous family with muscle
weakness, atrophy and contractures in three affected
individuals mapping the disease locus to chromosomal
region 1q25. We identified a homozygous deletion in a
novel nuclear-envelope related gene, torsinA-interacting
protein 1 (TOR1AIP1) encoding lamina-associated
polypeptide 1B (LAP1B). The mutation located in thefirst exon is predicted to cause a premature stop codon
and truncate the protein. Histological and molecular
analyses demonstrate that the protein is absent in the
patient’s myonuclei and indicate a critical role for
LAP1B in striated muscle tissue.2. Materials and methods
2.1. Patients
The study included a multiplex consanguineous Turkish
family with three affected individuals and healthy parents
(Fig. 1A). The individuals affected by a phenotype with
joint contractures were two siblings born to
consanguineous parents and their paternal cousin, who
was also born to consanguineous parents. Written
informed consent to participate in the study was obtained
from the patients and their family members. The study
protocol was approved by the Hacettepe University
Faculty of Medicine Ethics Committee (project number:
TBK 11/11-02).2.2. Histopathological studies
Muscle biopsy specimens obtained from the index case
(IV:5) (Fig. 1A) at age 13 years and her brother (IV:2)
(Fig. 1A) at age 36 years were evaluated. The shock-frozen
muscle samples were stained with a battery of routine
stains, including haematoxylin and eosin (H&E),
modified Gomori’s trichrome (MGT), periodic acid-Schiff
(PAS), Oil Red O (ORO), acid phosphatase, nicotine
adenine dinucleotide tetrazolium reductase (NADH-TR),
succinic dehydrogenase (SDH), cytochrome C oxidase
(COX) and ATPase. For immunohistochemical
examination by light microscopy, frozen sections (8 lm)
were incubated for 1 h at room temperature with anti-
merosin (1:20), anti-dystrophin (amino, rod and carboxyl
domains, 1:2), anti-alpha sarcoglycan (1:20), anti-desmin
(1:150), anti-emerin (1:20) and anti-lamin A/C (1:10)
antibodies (all from Novocastra), and for 1 h with
secondary antibodies. Dilutions and washing were
performed using phosphate buffered saline.
For immunofluorescent staining; after fixation in 4%
paraformaldehyde for 10 min and washing in phosphate
buffered saline (PBS), skeletal muscle sections (7 lm) were
blocked with 5% bovine serum albumin in PBS for 1 h at
room temperature. Incubation with the primary antibodies
anti-LAP1B (1:400, Merck Millipore), anti-torsinA (1:50,
Merck Millipore), anti-LULL1 (1:50, Sigma), anti-laminin
alpha-2 (1:2000, Chemicon), anti-lamin B (1:50, Santa
Cruz) and anti-PDI (1:100, Abcam) for 1 h at room
temperature was followed by washing with PBS and
labelling with Alexa Fluor 488 or 568 secondary antibody
(1:1000, Molecular Probes) for 45 min at room
temperature. After washing, DAPI staining, and mounting,
the sections were examined under an inverted fluorescent
Fig. 1. Clinical and histopathological findings. (A) Pedigree of the family. DNA samples were obtained from individuals II:4, III:1, III:2, III:3, III:4, IV:1,
IV:2, IV:3, IV:4, IV:5 and IV:7. Genome-wide homozygosity mapping was performed on affected members IV:2, IV:5, IV:7 and two healthy parents (III:1
and III:2) (wt: wild-type, m:mutant). (B and C) Clinical presentation of the index case (patient IV:5). (B) Thin appearance and (C) flexion contractures of
the fingers. (D) Muscle biopsy specimen obtained from the index case (patient IV:5) shows variation in fibre size, increase in internalized nuclei and a mild
increase in endomysial connective tissue. (E and F) Muscle biopsy specimen obtained from patient IV:2 shows variation in fibre size, many atrophic fibres,
increase in internal nuclei, rounded and a few angular fibres, rare subsarcolemmal vacuolar change (), and endomysial fibrosis—especially in the area of
atrophic fibres. Scale bars represent 50 lm.
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barrier filters.
2.3. Transmission electron microscopy
Muscle samples were carefully dissected, fixed in 2.5%
glutaraldehyde in phosphate buffer, rinsed in buffer andpost-fixed in 1% osmium tetroxide in phosphate buffer at
4 C for 2 h. Specimens were dehydrated in graded series
of ethanol to absolute ethanol in preparation for
embedding in epon (EMS) using an automated tissue
processor (Leica). Thin sections were stained with uranyl
acetate and lead citrate, and ultrastructural muscular
degeneration–regeneration criteria were analysed via a
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digital camera.
2.4. Genetic and molecular analyses
Genome-wide homozygosity mapping of the three
affected members (IV:2, IV:5 and IV:7) and two healthy
parents (III:1 and III:2) (Fig. 1A) was performed using
the Affymetrix GeneChip Human Mapping 250K NspI
Array. Genotype files (.chp) generated using Affymetrix
GTYPE software were analysed via VIGENOS (Visual
Genome Studio) software (Hemosoft, Ankara) [16].
Genome-wide haplotypes were constructed according to
data obtained from the index case (IV:5). Genes located
in the identified candidate region were identified using
NCBI Map Viewer (Annotation Release 104) and the
Ensembl database (Release 73.37).
DNA amplification and sequencing of all 10 exons and
exon–intron boundaries of TOR1AIP1 (NM_015602.3)
were performed using specific primers (see online
Supplementary Table S1). The Big Dye Terminator cycle
sequencing kit v.2.0 and the 3130 Genetic Analyser
sequencing instrument (Applied Biosystems) were used
for Sanger sequencing. The mutation was evaluated via
public databases including dbSNP (http://www.
ncbi.nlm.nih.gov/projects/SNP/), OMIM (http://www.
ncbi.nlm.nih.gov/omim) and NHLBI Exome Variant
Server (http://evs.gs.washington.edu/EVS/), and 154
healthy Turkish controls.
Total RNA was isolated from skeletal muscle biopsy
specimens obtained from case IV:2 and three healthy
controls using an RNeasy Fibrous Tissue kit (Qiagen),
according to the manufacturer’s instructions. RNA was
converted into cDNA via reverse transcription using a
QuantiTect Reverse Transcription kit (Qiagen), according
to the manufacturer’s instructions. Primers specific to
TOR1AIP1 and to ACTB were used with SYBR Green
JumpStart Taq ReadyMix (Sigma) and the experiments
were performed in triplicate (see online Supplementary
Table S2 for primers). Samples were analysed during the
same run and the experiments were repeated 3 times for
the same samples, and a no-template control was used
during each run. Ct values were normalized to ACTB.
Relative expression was obtained via the delta–delta Ct
method using Corbett Rotor-Gene 6000 series software
v.1.7 [17].
The total protein extracts concentration of patient IV:2
skeletal muscle, human control skeletal muscle, and liver
and kidney samples were assessed using bicinchoninic
acid assay. In total, 40 lg of each protein extract was
denatured via boiling and then subjected to 10% SDS/
PAGE. Following transfer to nitrocellulose membrane
and blocking, immunoblotting was performed with
primary antibodies anti-LAP1 (1:2500, a kind gift from
Dr. William T. Dauer) or anti-LULL1 (1:750, Sigma)
overnight at 4 C and IgG (H + L) HRP conjugate
secondary antibody (1:3000, Molecular Probes) for 1 h atroom temperature. Myosin bands shown by staining
with Coomassie Brilliant Blue and immunoblot with
HRP-conjugate anti-beta-actin (1:25,000, Abcam) were used
for equal loading control. ChemiFast chemiluminescence
substrate kit and GeneGnome chemiluminescence imaging




The index case (IV:5) (Fig. 1B) was a 29-year-old female
that had onset of proximal muscle weakness at age 7 years.
Currently, she can walk unaided but cannot rise from floor.
She has a thin appearance with flexion contractures of the
proximal and distal interphalangeal hand joints along with
a mild rigid spine in the cervical region (Fig. 1B and C).
Her serum creatine kinase (CK) level was 89 U L1
(normal range: 26–126 U L1). Electrocardiogram (ECG)
and echocardiogram performed at age 29 years were
normal. She had restriction in her pulmonary function:
FEV1 (forced expiratory volume in 1 s) was 43%.
Her 36 year-old brother (IV:2) was similarly affected. He
had his first symptoms at the age of 17 years as difficulty in
climbing stairs, which progressed to tiring in legs and
arms, and proximal and marked distal muscle weakness
within years. In addition to muscle weakness, he developed
contractures with spine, ankle and hand joint involvement.
There was marked atrophy in his interossei, abductor
pollicis brevis, and medial gastrocnemius muscles. He
could walk unaided for a distance of only 40 m. His serum
CK level was 483 U L1. Electromyography showed a
disseminated myogenic pattern, even in the most atrophied
dorsal interossei muscles. His cardiac evaluation
performed at age 36 showed mild diastolic and systolic
dysfunction with an ejection fraction of 57% via
echocardiography. Electrocardiogram was normal and
24 h Holter monitoring revealed normal sinus rhythm with
ventricular extrasystoles. Angiotensin-converting enzyme
inhibitor and beta blocker were initiated. He had moderate
restrictive respiratory function, with FEV1 of 63% via
spirometry. The siblings have a paternal cousin (IV:7) that
is also affected; however, she has not been clinically
investigated.
3.2. Histopathological findings
The muscle biopsy specimen from the vastus lateralis
muscle of the index case (IV:5) at age 13 years (Fig. 1D)
showed mild dystrophic features with variation in fibre
size, increase in internal nuclei and endomysial connective
tissue, and degeneration and phagocytosis in a few fibres.
Merosin, dystrophin, and alpha sarcoglycan immunohisto-
chemistry were normal. Vastus lateralis muscle biopsy of
the affected brother (IV:2) at age 35 years (Fig. 1E and
F) showed more prominent variation in fibre size and
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small fibres and a prominent increase in endomysial
connective tissue were observed (Fig. 1F). Some of the
atrophic fibres had relatively large nuclei that resembled
nuclear clumps of denervated fibres. A few fibres
exhibited vacuolar degeneration and some fibres exhibited
basophilic degeneration. There were no rimmed vacuoles.
Type 2 fibres predominated and atrophic fibres were of
both fibre types (type 1 and type 2). There was no
regeneration, inflammation, increase in lipid or glycogen,
or lysosomal activity. Lamin A/C and emerin
immunohistochemistry were normal, whereas some
fibres exhibited irregular desmin deposition (see online
Supplementary Fig. S1A). Further analyses were
performed using the muscle biopsy specimen of this
patient (IV:2).
Immunofluorescent staining showed a substantial loss of
LAP1B in the patient IV:2’s muscle, with a few scattered
nuclei staining positive (Fig. 2A). Double-labelling with
anti-LAP1B and anti-laminin alpha-2 antibodies showed
that the positive nuclear staining for LAP1B was not
within the muscle fibres but in the endomysial area
(Fig. 2B). Immunostaining of the patient’s muscle with
anti-lamin B, anti-LULL1 and anti-torsinA antibodies
was similar to control muscle (see online Supplementary
Fig. S1B–D). TorsinA and LULL1 appeared to be
distributed in the sarcoplasmic reticulum in both patient
and control muscle.Fig. 2. Immunofluorescent staining of skeletal muscle sections. (A) Immunolo
muscle were stained with anti-LAP1B (green) for 1 h at room temperature and
LAP1B was observed in patient IV:2’s muscle. Scale bars represent 200 lm.
anti-LAP1B and anti-laminin alpha-2 antibodies for 1 h at room temperature
represent 200 lm.3.3. Ultrastructural findings
Transmission electron microscopy exhibited intact
cytoplasmic sarcomeric organization with aligned Z
bands, good myofibril integrity and no sarcolemmal
disturbance at the ultrastructural level. A few centrally
located nuclei were noted and some nuclei exhibited
varying degrees of chromatin condensation and
aggregation. Nuclear fragmentation, chromatin bleb
formation and naked chromatin devoid of membrane
were evident as a consequence of nuclear membrane
disruption and karyoplasmic leakage into the
sarcoplasmic compartment (Fig. 3A–E). Variable degrees
of nuclear deformation were noted in about 40–60% of
the cell nuclei being trimmed for TEM. Vacuolar fibres
were not detected at the ultrastructural examination.
3.4. Genetic and molecular studies
Because of the initial limb-girdle muscular dystrophy-like
diagnosis, all known LGMD2 loci were previously excluded
via linkage analysis. Genome-wide homozygosity mapping
showed a single homozygous haplotype shared by the
three affected individuals on chromosomal region 1q25
(Fig. 4A). This region spanning approximately 1.8 Mb
resided between SNP markers rs316265 (SNP_A-1973844)
and rs16855014 (SNP_A-1802874). According to NCBI
Map Viewer (Annotation Release 104) and Ensemblcalization of LAP1B. Cross sections of patient IV:2 and control skeletal
DNA labelled with DAPI (blue). A substantial loss of nuclear staining of
(B) Double immunofluorescence staining of patient IV:2’s muscle with
. Arrows indicate positively stained nuclei in the interstitium. Scale bars
Fig. 3. Ultrastructural alterations of the nuclear envelope. (A) Nuclear fragmentation and chromatin bleb formation (arrow). (B) Nuclear membrane
disintegration and intranuclear canalicule formation (arrows). (C) A highly fragmented, degenerated nucleus, and adjacent naked chromatin (arrow). (D)
Nuclear disintegration with degenerating naked chromatin fragments (arrows). (E) High magnification of the crumbling and disintegration of the nuclear
envelope and subsequent naked chromatin fragment formation (arrows).
G. Kayman-Kurekci et al. / Neuromuscular Disorders 24 (2014) 624–633 629Genome Browser (Release 73.37) databases, this region
between 178.100.703 bp and 179.925.538 bp harboured
fifteen protein-coding genes among which TOR1AIP1
(MIM 614512) was selected as a candidate gene (see online
Supplementary Table S3). This gene encodes a type-2
integral membrane protein located in the inner nuclear
membrane, LAP1B. Because other proteins of the nuclearmembrane such as laminA/C, emerin, nesprin-1 and
nesprin-2 are known to cause muscular dystrophy
phenotypes, TOR1AIP1 was selected as a possible novel
nuclear envelopathy-related gene [14,15]. DNA sequencing
of TOR1AIP1 from the genomic DNA of affected
individuals IV:2, IV:5 and IV:7 showed that there was a
homozygous G deletion at position c.186 (c.186delG) in
Fig. 4. Homozygosity mapping and mutation analysis. (A) Representation of homozygosity mapping data. Genome-wide haplotypes were constructed
according to data obtained from the index case IV:5. Homozygous genotypes identical to the genotypes of the index case (IV:2) are shown in dark grey,
heterozygous genotypes appear in light grey. SNPs that are non-informative due to heterozygous genotypes in parent–child trios appear in white. The
single homozygous segment shared by the three affected individuals spanned approximately 1.8 Mb on chromosome 1 and is marked in the rectangle. (B)
DNA sequence chromatograms show homozygous c.186delG mutation in patient IV:2, heterozygous mutation in his mother (III:1) and wild-type
sequence in a control subject. (C) The mutation is predicted to cause a frameshift and a premature stop codon in the first exon.
630 G. Kayman-Kurekci et al. / Neuromuscular Disorders 24 (2014) 624–633the first exon of the gene, which was predicted to cause a
frameshift leading to a premature stop codon (Fig. 4B and
C). As a result, the 583 amino-acid protein is predicted to
be truncated to a non-functional protein 83 amino-acids in
length (p.E62fsTer25). The healthy parents (II:4, III:1,
III:2, III:3 and III:4) and siblings (IV:1, IV:3 and IV:4)
were heterozygous carriers and allele segregation in the
family was consistent with autosomal recessive
inheritance. The mutation was not detected in 154 healthy
controls of Turkish origin or in public SNP databases.
Expression of TOR1AIP1 mRNA was assessed via
qRT-PCR. Relative quantitation of TOR1AIP1 showed
that the level of expression in the skeletal muscle of
patient IV:2 was 5-fold lower than in three control
samples (Fig. 5A). The analysis of the expression profile
of the LAP1B protein via Western blotting showed a
total of two specific bands (Fig. 5B). The 66.3 kDa band
corresponding to LAP1B detected in control skeletal
muscle, liver, and kidney samples was absent in the
muscle of patient IV:2. An additional band with a
molecular weight of approximately 50 kDa present in all
samples appeared to be more abundant in the muscle of
patient IV:2 than in control muscle (Fig. 5B, ).
Immunoblotting with anti-LULL1 antibody showed thatexpression of LULL1 in the patient IV:2’s muscle was
greater than that in control muscle (Fig. 5B).
4. Discussion
We identified a novel nuclear envelope disease caused by a
homozygous mutation in TOR1AIP1, encoding LAP1B,
presenting as a myopathy with contractures. The study
patients developed proximal and severe distal weakness
and atrophy, rigid spine and contractures in the ankle and
small hand joints, as well as cardiac and respiratory
involvement. The extent of weakness and atrophy in the
distal muscles in patient IV:2 was similar to that associated
with longstanding neuropathy; however, electromyography
in these muscles showed myopathic potentials. Although
there were some fibres resembling nuclear clumps in
his muscle biopsy from the vastus lateralis, the
histopathological features were mainly compatible with a
myopathic process. In cases with muscle weakness, spinal
rigidity, contractures and cardiac involvement, lamin A/C
and emerin related EDMD must be considered in the
differential diagnosis. However, although the patients we
report here had rigidity of the spine and ankle
contractures, they did not have elbow contractures and the
Fig. 5. Expression analysis. (A) Analysis of TOR1AIP1 mRNA
expression via qRT-PCR. Primers bridging exon 1 and exon 2 of
TOR1AIP1 and primers specific to ACTB were used and the
experiments were performed in triplicate. Ct values for the control
samples and the patient muscle sample were normalized to ACTB.
Relative expression was obtained using the delta–delta Ct method [17].
Expression of TOR1AIP1 mRNA was 5-fold lower in patient IV:2 muscle
than in control samples. (B) Expression analysis of LAP1B protein based
on Western blotting. Protein extracts (40 lg) of patient IV:2 and control
skeletal muscle, and control liver and kidney samples were immunoblotted
via incubation of primary anti-LAP1 antibody overnight at 4 C and
HRP-conjugated secondary antibody for 1 h at room temperature.
Myosin bands shown via staining with Coomassie Brilliant Blue and
immunoblot with anti-beta-actin antibody were used for equal loading
control. A ChemiFast chemiluminescence substrate kit (Syngene) and
GeneGnome chemiluminescence imaging instrument (Syngene) were used
for chemiluminescence detection using 5-s exposure. The 66.3 kDa band
corresponds to LAP1B. One additional band of approximately 50 kDa
was observed (). Analysis of LULL1 expression via western blotting
showed that expression of LULL1 in the patient muscle was higher than in
the control muscle.
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finger contractures were not compatible with any known
EDMD phenotype [4,18]. In addition, pedigree was not
compatible with an X-linked disorder. Among other
diseases causing a contractural phenotype, marked distal
atrophy and cardiac involvement were unusual for
collagen VI related myopathies, joint laxity was not
present from the history or at physical examination [19].
Presence of cardiac features, distal involvement with
atrophy and contractures, and absence of early respiratoryinvolvement were not consistent with selenoprotein related
disease [20]. Ultrastructural alterations of the nuclear
envelope observed in the patient IV:2’s muscle, such as
disruption of the nuclear membrane, and chromatin
condensation and aggregation are consistent with the
nuclear envelope morphological abnormalities observed in
laminopathies (Fig. 3A–E) [21,22]. This pattern is
distinguishable from myopathic features which exhibit
degenerative ultrastructural changes starting from the
myocytic plasma membrane [23].
LAP1B encoded by TOR1AIP1 is type-2 integral
membrane protein located in the inner nuclear membrane
binding both A- and B-type lamins and involved in the
regulation of torsinA ATPase, a member of
AAA + ATPase family (ATPases associated with a variety
of cellular activities) known to be responsible for the
severe movement disorder DYT1 dystonia [7–12]. TorsinA
is diffusely distributed throughout the endoplasmic
reticulum and the nuclear envelope continuity but some
cell types exhibit a preference for the nuclear envelope
[24,25]. Luminal domain-like LAP1 (LULL1) encoded by
TOR1AIP2 is located in the endoplasmic reticulum and
shares homologous C-terminal regions with LAP1
allowing interaction with ER-located torsinA [11,24].
LAP1 and LULL1 appear to have arisen from a gene
duplication [11].
The c.186delG mutation in TOR1AIP1 is predicted to
cause a premature stop codon during translation,
truncating the 584 amino acid LAP1B protein to a
protein that is 86 amino acids in length (Fig. 4C). It is
predicted that the resulting mutant RNA is eliminated by
nonsense-mediated decay and that the truncated protein
is non-functional. Because no other isoform is described
in humans, we expected an absence of LAP1B in all
tissues, but our observations suggest that one LAP1
isoform—other than that expressed in myonuclei—might
be present in endomysial cells (Fig. 2B). Because the
endomysial cell population is greater in the dystrophic
muscle of the patient IV:2 than in the control muscle,
this isoform might correspond to the additional band of
around 50 kDa that was more abundant in the patient
IV:2’s muscle than in control muscle, but was also
present in liver and kidney samples (Fig. 5B, ).
Constitutive knockout of LAP1 in mice causes perinatal
lethality; however, a very recent study reported that the
conditional deletion of LAP1 from mouse striated muscle
leads to muscular dystrophy whereas LAP1 deletion from
hepatocytes does not affect liver function [13,26]. This
model supports the notion that LAP1B has a specific role
in striated muscle and represents a functional validation
of the effect of LAP1B deficiency in human striated
muscle. Data on the expression of LAP1 in different
species show that three different isoforms of LAP1 are
present in most tissues [7,9]. The present results show
that the 66.3 kDa isoform in human has a specific and
critical role in muscle tissue although it is also expressed
in the liver and kidneys.
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which causes the EDMD phenotype, strongly suggests
that LAP1 is as essential as emerin in striated muscle
function; however, the lack of a pathological phenotype
in emerin-null mice indicates that other factors are
involved in the function of the same proteins in different
species [26]. It is proposed that a higher level of
expression of LAP1 may compensate for the lack of
emerin in emerin deficient mice [26]. The same study also
reported that dislocalisation of emerin and lamin A/C in
nuclear foci was noted in approximately 10% of
myofibres isolated from the skeletal muscle of LAP1
muscle-specific conditional knockout mice [26]. In the
present study, immunostaining of lamin A/C, lamin B
and emerin did not show any difference of staining
pattern between patient IV:2 and control samples (see
online Supplementary Fig. S1A and B).
In contrast to LAP1 knockout mice exhibiting perinatal
lethality, loss of function of LAP1B in humans appears to
affect only muscle tissue, and a possible explanation is that
variation in the level of expression of the different LAP1
isoforms observed in mouse and human tissue, might
lead to different phenotypes in the case of loss of
function of LAP1 [26]. In the presented case, only the
66.3 kDa isoform was absent in muscle fibres. Another
hypothesis is that similar to emerin and LAP1
interaction, LULL1 might have a compensatory effect on
the phenotype in the absence of LAP1. Although no data
on LULL1 expression are provided in the mouse model,
overexpression of LULL1 in human might be related to
the relatively milder phenotype observed in humans, as
compared to mice.
Although knockdown of LAP1 or LULL1 does not seem
to affect expression or localization of torsinA, mice lacking
LAP1 exhibit perinatal lethality and LAP1 deficiency causes
nuclear membrane abnormalities similar to those observed
in torsinA-null cells [13,27]. On the other hand,
overexpression of LAP1 and LULL1 recruits torsinA to
the nuclear envelope [11,28]. A recent study reported that
ATPase activity of torsinA is induced in the presence of
LAP1 or LULL1 and that LAP1 and LULL1 are
regulatory cofactors of torsinA [12]. In agreement with
the literature, in the present study we did not observe any
change in the localization of torsinA or LULL1 in the
absence of LAP1B, as compared to control muscle (see
online Supplementary Fig. S1B and C); however, an
increase in expression of LULL1 was observed in the
patient IV:2 (Fig. 5B). It was suggested that LAP1 and
LULL1 have similar modes of action on torsinA and that
regulation of its ATPase activity is dependent on the dose
of its cofactors [12]. Furthermore, distribution of torsinA
might be regulated by the relative abundance of its
binding partners in the ER and the nuclear envelope [24].
According to these hypotheses, overexpression of LULL1
observed in the patient IV:2 might have been associated
with the absence of LAP1B and these two proteins might
have a compensatory effect on each other.Similar to other known nuclear envelopathies, in the
presented cases of TOR1AIP1 mutation there is a
tissue-specific phenotype caused by a mutation in a gene
that is apparently expressed ubiquitously [29]. Although
the exact mechanism of this tissue specificity remains
unknown, one model proposes that the nuclei of some cell
types, such as skeletal and cardiac muscle in the presented
cases are prone to an important mechanical stress and are
more susceptible than other cells [30]. The absence of
LAP1B in muscle might influence the structural and
mechanical stability of the nuclear envelope due to
impaired binding to the nuclear lamina. LAP1 is not the
sole torsinA partner localized in the nuclear envelope.
Other torsinA-binding partners, including components of
the LINC complex SUN1, SUN2 and nesprins, have been
described [27,31,32]. A possible consequence of LAP1B
deficiency might be altered interaction of cytoskeletal
components with the nuclear envelope via misbinding of
torsinA to other partners in the absence of LAP1B.
Although we did not observe any mislocalisation of
torsinA, its function might be altered without any
noticeable impact on its localization.
Another hypothesis is that defects of proteins in the
nuclear envelope might alter tissue-specific gene
expression patterns [29,30]. It is known that lamin A/C
and emerin are involved in muscle transcriptional
pathways [33–37]. One study proposed that LAP1 might
bind indirectly to mitotic chromosomes via a linker
protein [9]. If LAP1B has such a chromatin or
transcriptional regulator binding function, the
disturbance of heterochromatin organization observed in
the presented patient might influence expression of genes
specific to striated muscle.
In conclusion, we described a new autosomal recessive
nuclear envelope disease caused by a homozygous
mutation in exon 1 of TOR1AIP1 encoding LAP1B. The
clinical presentation of the present study patients
included proximal limb-girdle weakness during childhood
that progressed to distal weakness and contractures,
spinal rigidity and cardiomyopathy in adulthood. LAP1B
is an integral membrane protein of the inner nuclear
membrane known to bind A- and B-type lamins and
regulate torsinA ATPase activity. The muscle-restricted
phenotype suggests that LAP1B has a specific role in the
nuclear envelope of cardiac and skeletal muscle tissues.
In addition, overexpression of LULL1 in the absence of
LAP1 might support the hypothesis that these two
proteins act via the same pathway. The present study
expands the spectrum of genes associated with nuclear
envelopathies and highlights the critical function of
LAP1B in human striated muscle tissue.
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[20] Schara U, Kress W, Bönnemann CG, et al. The phenotype and
long-term follow-up in 11 patients with juvenile selenoprotein
N1-related myopathy. Eur J Paediatr Neurol 2008;12(3):224–30.
[21] Sewry CA, Brown SC, Mercuri E, et al. Skeletal muscle pathology in
autosomal dominant Emery–Dreifuss muscular dystrophy with lamin
A/C mutations. Neuropathol Appl Neurobiol 2001;27:281–90.
[22] Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated
cardiomyopathy with atrioventricular block: a lamin A/C defect-related
disease. J Am Coll Cardiol 2002;39:981–90.
[23] Cetin N, Balci-Hayta B, Gundesli H, et al. A novel desmin mutation
leading to autosomal recessive limb-girdle muscular dystrophy:
distinct histopathological outcomes compared with desminopathies.
J Med Genet 2013:1–7.
[24] Naismith TV, Dalal S, Hanson PI. Interaction of TorsinA with its
major binding partners is impaired by the dystonia-associated
deltaGAG deletion. J Biol Chem 2009;284:27866–74.
[25] Giles LM, Chen J, Li L, Chin L-S. Dystonia-associated mutations cause
premature degradation of torsinA protein and cell-type-specific
mislocalization to the nuclear envelope. Hum Mol Genet 2008;17:
2712–22.
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